483
Daiichi Sankyo Chemical Pharma Co., Ltd.Daiichi Sankyo Chemical Pharma Co., Ltd. – FDA 483, Dec 22, 2023
Record Details
An FDA inspection of Daiichi Sankyo Chemical Pharma Co., Ltd. in Iwaki, Fukushima, Japan, revealed significant deficiencies in quality control and production processes. The firm failed to thoroughly investigate unexplained discrepancies, out-of-specification results, and foreign matter, and lacked adequate production controls to prevent residue build-up in equipment during API manufacturing campaigns. These issues indicate a lack of robust quality systems to ensure drug product quality.
View Company Profile
ID · db84195a-9672-4125-97a9-d2d9e88a89b4
Other documents for Daiichi Sankyo Chemical Pharma Co., Ltd.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.